查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493176

免疫查核点抑制剂市场规模、份额、趋势分析报告：按类型、应用、分销管道、地区、细分市场预测，2024-2030

Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report By Type (PD-1, PD-L1, CTLA-4), By Application (Lung Cancer, Breast Cancer, Melanoma), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

免疫查核点抑制剂市场成长与趋势：

Grand View Research, Inc.最新报告预测，到2030年，全球免疫查核点抑制剂市场规模预计将达到1,542.5亿美元，2024年至2030年复合年增长率为17.9%。

癌症盛行率的增加以及 FDA 对免疫查核点抑制剂的核准增加推动了市场的成长。此外，增加资金以推动癌症免疫治疗，加上研究机构和主要参与者不断增加的研发活动，进一步推动了市场成长。

多种癌症盛行率的上升以及对适当治疗方案的需求不断增长预计将推动市场成长。例如，根据国际癌症研究机构 (IARC) 的数据，预计 2023 年将出现超过 2,070 万名新癌症患者。此外，根据乳癌统计和资源的数据，2020 年全球约有 230 万名女性被诊断出罹患乳癌。此外，医疗保健专业人员和患者对化疗和放射线治疗副作用的认识不断提高，是影响免疫查核点抑制剂等替代疗法成长的主要因素。

癌症免疫治疗资金的增加预计将在不久的将来为市场提供利润丰厚的机会。各国政府和主要机构不断致力于透过鼓励研究和开发活动来医疗费用支出，其中包括免疫查核点抑制剂。例如，2023 年 7 月，癌症研究所津贴约 2,800 万美元，以促进免疫疗法的创新。同样，2021 年 7 月，兰金政府宣布投资 1,800 万美元，用于改善癌症治疗，包括免疫查核点抑制剂。诸如此类的措施正在推动市场成长。

然而，免疫查核点抑制剂在癌症治疗中的高相关成本和併发症带来了重大挑战。用于癌症治疗的免疫查核点抑制剂可能会引起免疫相关的不利事件。这些併发症包括皮肤问题、胃肠道疾病（如结肠炎）、内分泌功能障碍、肺炎、风湿病、神经和心臟併发症以及肾臟问题。 ICI 对癌症显示出强大的功效，预计这些副作用将阻碍预测期内的市场成长。

免疫查核点抑制剂市场报告亮点

  • 按产品类型划分，由于研发活动活性化、产品核可增加以及Pembrolizumab和纳武单抗等药物处方的快速增加，PD-1细分市场在2023年以73.3%的最大销售份额引领市场。
  • 从应用来看，肺癌领域占市场最大，2023年销售量为25.41%。肺癌患者数量的增加是推动该细分市场成长的关键因素。
  • 从应用来看，大肠直肠癌领域预计在预测期内将以最快的复合年增长率成长。
  • 按分销管道划分，由于药品采购的可及性和便利性提高，预计线上药局领域在预测期内将以最快的复合年增长率成长。
  • 由于癌症盛行率上升、购买力平价高、政府对优质医疗保健的支持以及可报销等因素，北美在 2023 年以 62.81% 的销售份额占据市场主导地位。
  • 2023年3月，BioNTech与OncoC4建立策略联盟，开始共同开发和商业化适用于多种固体癌的新型免疫检查查核点抑制剂抗CTLA-4单株抗体候选药物。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章免疫查核点抑制剂市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 免疫查核点抑制剂市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析
    • 管道分析

第四章 免疫查核点抑制剂市场：类型估计与趋势分析

  • 全球免疫查核点抑制剂市场：类型仪表板
  • 全球免疫查核点抑制剂市场：类型变异分析
  • 按类型分類的收益
  • PD-1
  • PD-L1
  • CTLA-4
  • 其他的

第五章 免疫查核点抑制剂市场：应用预估及趋势分析

  • 全球免疫查核点抑制剂市场：应用仪表板
  • 全球免疫查核点抑制剂市场：应用变化分析
  • 按使用情况分類的收益
  • 肺癌
  • 乳癌
  • 膀胱癌
  • 恶性黑色素瘤
  • 子宫颈癌
  • 何杰金氏淋巴瘤
  • 大肠直肠癌
  • 其他的

第六章 免疫查核点抑制剂市场：通路估算及趋势分析

  • 全球免疫查核点抑制剂市场：分销通路仪表板
  • 全球免疫查核点抑制剂市场：通路波动分析
  • 按分销管道分類的收益
  • 医院药房
  • 零售药房
  • 网路药房

第七章免疫查核点抑制剂市场：区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030 年市场规模、预测与分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • Sanofi
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Regeneron Pharmaceuticals Inc.
    • AstraZeneca PLC
    • Shanghai Jhunsi Biosciences Ltd
    • Immutep Ltd
    • BeiGene Ltd
    • GlaxoSmithKline PLC
Product Code: GVR-4-68040-257-4

Immune Checkpoint Inhibitors Market Growth & Trends:

The global immune checkpoint inhibitors market size is anticipated to reach USD 154.25 billion by 2030 and is projected to grow at a CAGR of 17.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by increasing prevalence of cancer, and growing FDA approvals of immune checkpoint inhibitors. Moreover, increasing funding for advancing cancer immunotherapy coupled with rising R&D activities by research institutes and key operating players are further impelling market growth.

The rise in prevalence of multiple cancers and increase in need for appropriate treatment options are anticipated to drive market growth. For instance, according to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases were expected in 2023.In addition, according to the Breast Cancer Statistics and Resources, about 2.3 million women were diagnosed with breast cancer across the globe in 2020. Moreover, increased awareness among healthcare providers and patients about the adverse effects of chemotherapy & radiation therapy is a primary factor influencing the growth of alternative therapeutics, such as immune checkpoint inhibitors.

Growing funding for cancer immunotherapy is anticipated to offer lucrative opportunities for the market in the near future. Government and key organizations engage constantly in activities intended at curbing cancer immunotherapy healthcare expenditure by encouraging R&D activities to advance cancer immunotherapy including immune checkpoint inhibitors. For instance, in July 2023, the Cancer Research Institute awarded about USD 28 million in grants to boost innovations in immunotherapy. Similarly, in July 2021, the Rankin government announced an investment of USD 18 million to improve cancer therapy including immune checkpoint inhibitors. Such initiatives are driving market growth.

However, the high cost associated and complications of immune checkpoint inhibitors in cancer therapy pose a significant challenge. Immune checkpoint inhibitors for cancer treatment can lead to immune-related adverse events. These complications include skin issues, gastrointestinal problems like colitis, endocrine dysfunctions, pulmonary inflammation, rheumatologic symptoms, nervous system and cardiac complications, and renal issues. Although ICIs show significant success against cancer, these side effects are anticipated to hamper market growth during the forecast period.

Immune Checkpoint Inhibitors Market Report Highlights:

  • Based on type, the PD-1 segment led the market with the largest revenue share of 73.3% in 2023, owing to growing R&D activities, increasing product approvals and surge in prescription of drugs such as pembrolizumab and nivolumab
  • Based on application, the lung cancer segment held the market with the largest revenue share of 25.41% in 2023. Increase in number of lung cancer cases is a significant factor driving growth of this segment
  • Based on application, the colorectal cancer segment is expected to grow at the fastest CAGR over forecast period
  • Based on the distribution channel, the online pharmacy segment is expected to grow at the fastest CAGR over the forecast period, owing to the increasing accessibility and convenience of drug procurement
  • North America dominated the market with the revenue share of 62.81% in 2023, owing to factors such as increasing prevalence of cancer, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
  • In March 2023, BioNTech, entered into strategic collaboration with OncoC4 to co-develop and commercialize new immune checkpoint inhibitor anti-CTLA-4 monoclonal antibody candidate for multiple solid tumor indications.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in Asia Pacific
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Immune Checkpoint Inhibitors Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Increasing R&D investments
      • 3.2.1.3. Rise in healthcare spending
      • 3.2.1.4. New product approvals and launches
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of immune checkpoint inhibitors
  • 3.3. Immune Checkpoint Inhibitors Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis

Chapter 4. Immune Checkpoint Inhibitors Market: Type Estimates & Trend Analysis

  • 4.1. Global Immune Checkpoint Inhibitors Market: Type Dashboard
  • 4.2. Global Immune Checkpoint Inhibitors Market: Type Movement Analysis
  • 4.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Type, Revenue (USD Million)
  • 4.4. PD-1
    • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. PD-L1
    • 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. CTLA-4
    • 4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Immune Checkpoint Inhibitors Market: Application Estimates & Trend Analysis

  • 5.1. Global Immune Checkpoint Inhibitors Market: Application Dashboard
  • 5.2. Global Immune Checkpoint Inhibitors Market: Application Movement Analysis
  • 5.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Application, Revenue (USD Million)
  • 5.4. Lung Cancer
    • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Breast Cancer
    • 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Bladder Cancer
    • 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Melanoma
    • 5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Cervical Cancer
    • 5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.9. Hodgkin Lymphoma Cancer
    • 5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.10. Colorectal Cancer
    • 5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Immune Checkpoint Inhibitors Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Immune Checkpoint Inhibitors Market: Distribution Channel Dashboard
  • 6.2. Global Immune Checkpoint Inhibitors Market: Distribution Channel Movement Analysis
  • 6.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Immune Checkpoint Inhibitors Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Sanofi
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. F. Hoffmann-La Roche Ltd.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Bristol-Myers Squibb Company
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Eli Lilly and Company
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Regeneron Pharmaceuticals Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AstraZeneca PLC
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Shanghai Jhunsi Biosciences Ltd
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Immutep Ltd
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. BeiGene Ltd
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. GlaxoSmithKline PLC
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Europe immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 14 Europe immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Germany immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 U.K. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 20 U.K. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 21 U.K. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 23 France immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 24 France immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Italy immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 26 Italy immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Spain immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 29 Spain immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Denmark immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Sweden immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Norway immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 China immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 45 China immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 46 China immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Japan immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 48 Japan immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 49 Japan immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 India immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 51 India immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 52 India immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 South Korea immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 54 South Korea immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Korea immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Australia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 57 Australia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 58 Australia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Thailand immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 60 Thailand immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 61 Thailand immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Latin America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 63 Latin America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 64 Latin America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Brazil immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 66 Brazil immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 67 Brazil immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 68 Mexico immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 69 Mexico immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 70 Mexico immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Argentina immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 72 Argentina immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 73 Argentina immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 MEA immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 76 MEA immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 South Africa immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 79 South Africa immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 80 South Africa immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 UAE immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 85 UAE immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 86 UAE immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Kuwait immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 88 Kuwait immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 89 Kuwait immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in APAC
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Immune checkpoint inhibitors market: market outlook
  • Fig. 10 Immune checkpoint inhibitors competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Immune checkpoint inhibitors market driver impact
  • Fig. 16 Immune checkpoint inhibitors market restraint impact
  • Fig. 17 Immune checkpoint inhibitors market strategic initiatives analysis
  • Fig. 18 Immune checkpoint inhibitors market: Type movement analysis
  • Fig. 19 Immune checkpoint inhibitors market: Type outlook and key takeaways
  • Fig. 20 PD-1 market estimates and forecast, 2018 - 2030
  • Fig. 21 PD-L1 estimates and forecast, 2018 - 2030
  • Fig. 22 CTLA-4 market estimates and forecast, 2018 - 2030
  • Fig. 23 Others estimates and forecast, 2018 - 2030
  • Fig. 24 Immune checkpoint inhibitors market: Application movement analysis
  • Fig. 25 Immune checkpoint inhibitors market: Application outlook and key takeaways
  • Fig. 26 Lung cancer market estimates and forecasts, 2018 - 2030
  • Fig. 27 Breast cancer market estimates and forecasts,2018 - 2030
  • Fig. 28 Bladder cancer market estimates and forecasts,2018 - 2030
  • Fig. 29 Melanoma market estimates and forecasts, 2018 - 2030
  • Fig. 30 Cervical cancer market estimates and forecasts,2018 - 2030
  • Fig. 31 Hodgkin lymphoma market estimates and forecasts,2018 - 2030
  • Fig. 32 Colorectal cancer market estimates and forecasts, 2018 - 2030
  • Fig. 33 Others market estimates and forecasts,2018 - 2030
  • Fig. 34 Immune checkpoint inhibitors market: Distribution channel movement analysis
  • Fig. 35 Immune checkpoint inhibitors market: Distribution channel outlook and key takeaways
  • Fig. 36 Hospital pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 37 Retail pharmacies market estimates and forecasts,2018 - 2030
  • Fig. 38 Online pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 39 Global immune checkpoint inhibitors market: Regional movement analysis
  • Fig. 40 Global immune checkpoint inhibitors market: Regional outlook and key takeaways
  • Fig. 41 Global immune checkpoint inhibitors market share and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America, by country
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 US market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030
  • Fig. 53 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 54 France market estimates and forecasts, 2018 - 2030
  • Fig. 55 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 56 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 57 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 61 China market estimates and forecasts, 2018 - 2030
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 63 India market estimates and forecasts, 2018 - 2030
  • Fig. 64 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 65 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 66 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 67 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 68 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 69 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 74 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 76 Market share of key market players - Immune checkpoint inhibitors market